Royal Bank of Canada
PRVL

Royal Bank of Canada’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Royal Bank of Canada’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,171
Closed -$27K – 7950
2020
Q4 		$27K Buy
1,171
+271
+30% +$3.44K ﹤0.01% 5934
2020
Q3 		$9K Sell
900
-21
-2% -$282 ﹤0.01% 5980
2020
Q2 		$14K Sell
921
-53
-5% -$816 ﹤0.01% 5731
2020
Q1 		$12K Sell
974
-515
-35% -$8.19K ﹤0.01% 5783
2019
Q4 		$23K Buy
+1,489
New +$19K ﹤0.01% 5809

Royal Bank of Canada's PRVL Position: Q1 2021 in Review

Royal Bank of Canada sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 1,171 shares — an estimated $27K sold.

Royal Bank of Canada first reported a position in PRVL in Q4 2019 and held it in 5 quarters. The position peaked at $27K in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Royal Bank of Canada reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Royal Bank of Canada sold 1,171 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $27K.
  • Royal Bank of Canada first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2019 and held it in 5 quarters.
  • Royal Bank of Canada's Prevail Therapeutics Inc. Common Stock position peaked at $27K in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Royal Bank of Canada's 13F filing for Q1 2021, filed 17 May 2021.